



(51) International Patent Classification:

A61K 51/04 (2006.01) C07B 59/00 (2006.01)

A61K 51/08 (2006.01)

(21) International Application Number:

PCT/US2022/025933

(22) International Filing Date:

22 April 2022 (22.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/179,089 23 April 2021 (23.04.2021) US

(71) Applicant: FUSION PHARMACEUTICALS INC.

[CA/CA]; 270 Longwood Road South, Hamilton, Ontario L8P 0A6 (CA).

(72) Inventors: BURAK, Eric S.; 40 James Street, Cambridge,

Ontario N1S 1C5 (CA). FORBES, John R.; 2210 Irving Street, Burlington, Ontario L7L 6T3 (CA). SIMMS, Ryan W.; 70 Thirteenth Street, Toronto, Ontario M8V 3H6 (CA).

(74) Agent: BIEKER, Kristina et al.; Goodwin Procter LLP, 100 Northern Avenue, IP DOCKETING DEPT./7TH FL, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: METHODS FOR TREATMENT OF CANCERS




FIG. 1

(57) **Abstract:** The present disclosure relates to methods of treating a subject having cancer with an ^{225}Ac -radiopharmaceutical, which comprises ^{225}Ac chelated with a compound of Formula (I) wherein the compound binds to neurotensin receptor 1 (NTSR1) and does not cross the blood-brain barrier, and wherein the ^{225}Ac -radiopharmaceutical is administered at a dosage of less than 10 MBq/kg of body weight of the subject or is administered as a unitary dosage of less than 40 MBq to the subject.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*